Literature DB >> 25755744

High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival.

Siya Zhang1, Xiaolu Zhai1, Gui Wang2, Jian Feng2, Huijun Zhu3, Liqin Xu2, Guoxin Mao1, Jianfei Huang3.   

Abstract

Melanoma associated antigen-A (MAGE-A) is an oncogene and correlated with tumor initiation and development. However the roles of MAGE-A9 in non-small cell lung cancer (NSCLC) are still unknown. We investigated MAGE-A9 mRNA expression in 18 tumor tissues of NSCLC by qRT-PCR and MAGE-A9 protein expression in 213 NSCLC samples of tissue arrays by immunohistochemical staining. We assessed the relationship between MAGE-A9 expression and clinical parameters. The results showed that the high expression of MAGE-A9 protein in NSCLC tumor cells were commonly present in squamous cell carcinomas (P = 0.030). It was also related to larger tumor diameter, lymph node metastasis and later stage grouping with TNM classification (all P < 0.05). Whereas the expression of MAGE-A9 in stromal cells was higher in squamous cell carcinomas as well. Cox regression univariate and multivariable analysis revealed that MAGE-A9 expression in tumor cells of NSCLC (P < 0.001) is an independent prognostic factor in five-year overall survival rate. We concluded that the molecular assessment of MAGEA9 could be considered to improve prognostic evaluation and to identify eligible patients for potential target therapy.

Entities:  

Keywords:  Melanoma associated antigen-A 9; immunohistochemistry; non-small cell lung cancer; prognosis; stromal; tumor cell

Mesh:

Substances:

Year:  2015        PMID: 25755744      PMCID: PMC4348844     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  52 in total

1.  Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.

Authors:  Sara J Adair; Kevin T Hogan
Journal:  Cancer Immunol Immunother       Date:  2008-09-13       Impact factor: 6.968

2.  Evaluation of MAGE A1 in oral squamous cell carcinoma.

Authors:  Cláudia Maria Pereira; Carolina Cavaliéri Gomes; Jeane De Fátima Correia Silva; Monica Bucciarelli Rodriguez; Alvimar Afonso Barbosa; Ricardo Santiago Gomez
Journal:  Oncol Rep       Date:  2012-03-19       Impact factor: 3.906

Review 3.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

4.  The clinical significance of MAGEA3 expression in pancreatic cancer.

Authors:  Joseph Kim; Howard A Reber; Oscar J Hines; Kevork K Kazanjian; Andy Tran; Xing Ye; Farin F Amersi; Steve R Martinez; Sarah M Dry; Anton J Bilchik; Dave S B Hoon
Journal:  Int J Cancer       Date:  2006-05-01       Impact factor: 7.396

5.  Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.

Authors:  Martin Bolli; Thomas Kocher; Michel Adamina; Ulrich Guller; Peter Dalquen; Philippe Haas; Martina Mirlacher; Franco Gambazzi; Felix Harder; Michael Heberer; Guido Sauter; Giulio C Spagnoli
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

6.  Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis.

Authors:  Tobias Peikert; Ulrich Specks; Carol Farver; Serpil C Erzurum; Suzy A A Comhair
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

7.  A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells.

Authors:  Toshiharu Sakurai; Katsuhiko Itoh; Hiroaki Higashitsuji; Toshikazu Nagao; Kohsuke Nonoguchi; Tsutomu Chiba; Jun Fujita
Journal:  J Biol Chem       Date:  2004-01-22       Impact factor: 5.157

Review 8.  GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

Authors:  Vincent G Brichard; Diane Lejeune
Journal:  Vaccine       Date:  2007-09-27       Impact factor: 3.641

Review 9.  Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.

Authors:  Karen Kelly; Chao Huang
Journal:  J Thorac Oncol       Date:  2008-06       Impact factor: 15.609

10.  Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.

Authors:  Sang Hyun Kim; Sangyull Lee; Chang Hun Lee; Min Ki Lee; Young Dae Kim; Dong Hoon Shin; Kyung Un Choi; Jee Yeon Kim; Do Youn Park; Mee Young Sol
Journal:  Lung       Date:  2009-10-01       Impact factor: 2.584

View more
  12 in total

Review 1.  A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.

Authors:  Anna K Lee; Patrick Ryan Potts
Journal:  J Mol Biol       Date:  2017-03-11       Impact factor: 5.469

2.  Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden.

Authors:  Yunlong Cui; Ning Jiang
Journal:  Hum Cell       Date:  2022-05-27       Impact factor: 4.174

3.  DDX17 promotes the growth and metastasis of lung adenocarcinoma.

Authors:  Xiaohui Liu; Lu Li; Chengjie Geng; Shiyuan Wen; Cuiqiong Zhang; Chunmiao Deng; Xuejuan Gao; Gong Zhang; Qing-Yu He; Langxia Liu
Journal:  Cell Death Discov       Date:  2022-10-22

Review 4.  The MAGE protein family and cancer.

Authors:  Jenny L Weon; Patrick Ryan Potts
Journal:  Curr Opin Cell Biol       Date:  2015-09-03       Impact factor: 8.382

5.  High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma.

Authors:  Xiaolu Zhai; Liqin Xu; Siya Zhang; Huijun Zhu; Guoxin Mao; Jianfei Huang
Journal:  Oncotarget       Date:  2016-01-26

6.  MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer.

Authors:  Lina Gu; Meixiang Sang; Danjing Yin; Fei Liu; Yunyan Wu; Shina Liu; Weina Huang; Baoen Shan
Journal:  Thorac Cancer       Date:  2018-02-12       Impact factor: 3.500

7.  High expression of MAGE-A9 is associated with unfavorable survival in esophageal squamous cell carcinoma.

Authors:  Yu Qi; Ke Xin Cao; Fu Chen Xing; Chun Yang Zhang; Qi Huang; Kai Wu; Feng Biao Wen; Song Zhao; Xin Li
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

8.  Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA).

Authors:  Magdalena Niemira; Francois Collin; Anna Szalkowska; Agnieszka Bielska; Karolina Chwialkowska; Joanna Reszec; Jacek Niklinski; Miroslaw Kwasniewski; Adam Kretowski
Journal:  Cancers (Basel)       Date:  2019-12-21       Impact factor: 6.639

9.  Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression.

Authors:  Yiu Huen Tsang; Yumeng Wang; Kathleen Kong; Caitlin Grzeskowiak; Oksana Zagorodna; Turgut Dogruluk; Hengyu Lu; Nicole Villafane; Venkata Hemanjani Bhavana; Daniela Moreno; Sarah H Elsea; Han Liang; Gordon B Mills; Kenneth L Scott
Journal:  Elife       Date:  2020-04-09       Impact factor: 8.140

10.  Prognostic Value of Melanoma-Associated Antigen-A (MAGE-A) Gene Expression in Various Human Cancers: A Systematic Review and Meta-analysis of 7428 Patients and 44 Studies.

Authors:  Manish Poojary; Padacherri Vethil Jishnu; Shama Prasada Kabekkodu
Journal:  Mol Diagn Ther       Date:  2020-10       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.